Abstract:The epidemiology of IFD following pediatric heart transplantation (pHT) is poorly characterized. We sought to evaluate use of antifungal prophylaxis and describe the epidemiology of IFD in pHT at two large children's hospitals. We performed a retrospective cohort study of pediatric and young adult (≤21 years) patients undergoing heart transplantation at Cincinnati Children's Hospital Medical Center (CCHMC) and Children's Hospital of Philadelphia (CHOP) between 2012 and 2021. We recorded demographic, clinical, medication, and laboratory data for pHT patients through 12 months post-transplant. We identified use of topical (oral nystatin) and systemic antifungal prophylaxes in the peri-transplant period (7 days prior through 14 days following transplant) and analyzed if certain transplant variables were associated with the administration of systemic antifungals during this period using rank sum and chi squared tests. Applying published definitions, we quantified the incidence of proven and probable IFD and explored the characteristics of these cases. A total of 201 patients underwent heart transplant at CCHMC and CHOP. The majority were male (60.2%), White (66.7%), and not Hispanic or Latino (88.1%). Median age at time of transplant was 7.4 years (IQR 0.9-14.2). During the peri-transplant period, 143 (71.1%) patients received oral nystatin and 37 (18.4%) received systemic antifungal prophylaxis, not including PJP prophylaxis. 41 individuals (20.4%) were not on any antifungal prophylaxis throughout this period. Delayed chest closure was significantly associated with the administration of systemic antifungals (p<0.001) while several other variables (age, hospital, immunosuppression medication, ECMO/LVAD pre-transplant) were not. In total, 8 patients (4%) developed proven (n=5) or probable (n=3) IFD. In our cohort, the incidence rate of proven/probable IFD in the first year post-transplant was 44.8 per 1000 patient-years. The characteristics of these cases are shown in Table 1. Time from pHT to IFD ranged from 11 days to 196 days (median time = 25.5 days). All cases of proven IFD occurred within 28 days of transplant. In three cases of proven/probable IFD, patients were receiving a systemic antifungal or PJP prophylaxis in the seven days prior to IFD onset. Two cases met the definition of probable IFD but the infections resolved without directed therapies. Four patients with proven IFD died within 1 year following transplant, although in only 3 cases was IFD a contributing factor. The one-year all-cause mortality rate among pHT patients with proven/probable IFD (50%) was higher than that in pHT patients without IFD (10.3%; Fisher's exact p=0.008). Over a 10-year period at CCHMC and CHOP, 4% of pHT patients developed proven or probable IFD within one-year post-transplant. All proven IFD cases occurred within a month of transplant while probable cases occurred more than 100 days post-transplant. Delayed chest closure was significantly associated with the administration of systemic antifungal prophylaxis. Patients with proven IFD had poor outcomes despite receipt of appropriate antifungal treatment. Given the low incidence of IFD at these two centers, we were unable to evaluate risk factors for IFD in this population and so larger studies would be needed. Table 1 Characteristics of patient with proven or probable invasive fungal disease Abbreviations: IFD, invasive fungal disease; NOS, not otherwise specified. Seen on microscopic examination of peritoneal fluid but did not grow on culture. Diagnosed on respiratory culture, with positive bronchoalveolar lavage cytology and imaging concerning for pulmonary fungal disease. Positive antigen testing in serum in the setting of pulmonary nodules. Positive PCR on sputum specimen in patient with pulmonary infiltrates. Patient died within one year of transplant but unrelated to IFD. Table 1 Characteristics of patient with proven or probable invasive fungal disease Abbreviations: IFD, invasive fungal disease; NOS, not otherwise specified. Seen on microscopic examination of peritoneal fluid but did not grow on culture. Diagnosed on respiratory culture, with positive bronchoalveolar lavage cytology and imaging concerning for pulmonary fungal disease. Positive antigen testing in serum in the setting of pulmonary nodules. Positive PCR on sputum specimen in patient with pulmonary infiltrates. Patient died within one year of transplant but unrelated to IFD.

Incidence and outcomes of invasive fungal infection among solid organ transplant recipients: A population‐based cohort study

Invasive Fungal Infections in Inpatient Solid Organ Transplant Recipients With COVID-19: A Multicenter Retrospective Cohort

Invasive fungal infections in liver transplantation.

Long‐term outcomes after COVID‐19 infection in transplant recipients

2714. Invasive Fungal Disease in Lung Transplant Recipients: Incidence, Risk Factors, and Outcomes

Monocentric, Retrospective Study on Infectious Complications within One Year after Solid-Organ Transplantation at a Belgian University Hospital

Invasive Fungal Infection in Hematopoietic Stem Cell Transplant Recipient from an Indian Oncology Setting

Impact of Invasive Fungal Infection on Outcomes of Severe Sepsis: a Multicenter Matched Cohort Study in Critically Ill Surgical Patients

Invasive Fungal Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Single Center Experiences of 12 Years

Outcomes in solid organ transplant recipients receiving organs from a donor with Fusarium solani species complex meningitis

Impact of solid organ transplant status on outcomes of hospitalized patients with COVID‐19 infection

The Incidence and Risk Factors of Invasive Fungal Infection after Haploidentical Haematopoietic Stem Cell Transplantation Without in Vitro T-cell Depletion

Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation.

Clinical Characteristics and Outcomes of Endemic Mycoses after Solid Organ Transplantation: A Comprehensive Review

Hospitalizations for opportunistic infections following transplantation and associated risk factors: A national cohort study of Medicare beneficiaries

Invasive Fungal Disease in Pediatric Heart Transplant Recipients

Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study

[The Prevalence and Risk Factors of Invasive Fungal Infection in Hematopoietic Stem Cell Transplant Recipients].

Impact of preoperative infection on the outcomes of liver transplant recipients: a national propensity score-matched retrospective cohort study in China

Epidemiology and Prognosis of Invasive Fungal Disease in Chinese Lung Transplant Recipients

High risk of osteoporosis and fracture following solid organ transplantation: a population-based study